Literature DB >> 27259045

Tissue reservoirs of HIV.

Joseph K Wong1, Steven A Yukl.   

Abstract

PURPOSE OF REVIEW: Tissue reservoirs of HIV may promote the persistent immunopathology responsible for non-AIDS morbidity and data support multifocal reactivation from tissues as the source of viral rebound during antiretroviral therapy (ART) interruption. The heterogeneity of tissue reservoirs and incomplete knowledge about their composition are obstacles to an HIV cure. RECENT
FINDINGS: In addition to the higher concentration of infected CD4 T cells found in both central lymphoid tissues and gut, specific subsets of CD4 T cells appear to play a disproportionate role in HIV persistence. Recently, a subset of central memory T cells enriched in lymph node germinal centers called T-follicular helper cells has been identified that expresses more viral RNA and occupies an anatomic niche inaccessible to cytotoxic T lymphocyte killing. Additional observations suggest that antiretroviral drug (ARV) concentrations may be lower in some tissues, raising the possibility for localized, low-level viral replication. Finally, some recent data implicate the persistence of infected, non-CD4 T-cell types in tissues during ART.
SUMMARY: The retention of infected cells in a wide variety of tissues, often with distinct viral and cellular characteristics, underscores the importance of studying tissue reservoirs in the development and assessment of cure strategies. Both inhibitory ARVs and latency-reversing drugs must reach these sites, and novel strategies may be needed to attack virus in cells as variable as T-follicular helper cells and macrophages.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27259045      PMCID: PMC4928570          DOI: 10.1097/COH.0000000000000293

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  145 in total

1.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

2.  Rectal cell-associated HIV-1 RNA: a new marker ready for the clinic.

Authors:  Alain Lafeuillade; Antoine Cheret; Gilles Hittinger; David Bernardini; Caroline Cuquemelle; Eric Jullian; Cécile Poggi
Journal:  HIV Clin Trials       Date:  2009 Sep-Oct

3.  An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.

Authors:  Guillaume Mousseau; Mark A Clementz; Wendy N Bakeman; Nisha Nagarsheth; Michael Cameron; Jun Shi; Phil Baran; Rémi Fromentin; Nicolas Chomont; Susana T Valente
Journal:  Cell Host Microbe       Date:  2012-07-19       Impact factor: 21.023

4.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease.

Authors:  D C Kalter; J J Greenhouse; J M Orenstein; S M Schnittman; H E Gendelman; M S Meltzer
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

6.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood.

Authors:  J Overbaugh; R J Anderson; J O Ndinya-Achola; J K Kreiss
Journal:  AIDS Res Hum Retroviruses       Date:  1996-01-20       Impact factor: 2.205

8.  Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations.

Authors:  Grissell Tirado; Gloria Jove; Rakesh Kumar; Richard J Noel; Evelyn Reyes; Gladys Sepulveda; Y Yamamura; Anil Kumar
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

View more
  99 in total

Review 1.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Salvage Antiretroviral Therapy: Time for "DeNUKElearization"?

Authors:  Martin Hoenigl; Susan J Little
Journal:  J Infect Dis       Date:  2020-04-07       Impact factor: 5.226

Review 3.  HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Authors:  Corbin G Thompson; Cynthia L Gay; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

4.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 5.  The microbiome and HIV persistence: implications for viral remission and cure.

Authors:  Wei Li A Koay; Lilly V Siems; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2018-01       Impact factor: 4.283

6.  Identification, Localization, and Quantification of HIV Reservoirs Using Microscopy.

Authors:  Lisa Prevedel; Nancy Ruel; Paul Castellano; Carla Smith; Shaily Malik; Courtney Villeux; Morgane Bomsel; Susan Morgello; Eliseo A Eugenin
Journal:  Curr Protoc Cell Biol       Date:  2018-09-28

Review 7.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

8.  LEDGINs, Inhibitors of the Interaction Between HIV-1 Integrase and LEDGF/p75, Are Potent Antivirals with a Potential to Cure HIV Infection.

Authors:  Zeger Debyser; Anne Bruggemans; Siska Van Belle; Julie Janssens; Frauke Christ
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition.

Authors:  Jie-Hua Jin; Hui-Huang Huang; Ming-Ju Zhou; Jing Li; Wei Hu; Lei Huang; Zhe Xu; Bo Tu; Guang Yang; Ming Shi; Yan-Mei Jiao; Xing Fan; Jin-Wen Song; Ji-Yuan Zhang; Chao Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2020-03-24       Impact factor: 11.530

10.  Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.

Authors:  Armin Sepp; Mats Bergström; Marie Davies
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.